ClinicalTrials.gg
RecruitingNCT06967597FUGITIVEUpdated Jun 10, 2025

Conservative Versus Proactive Management of Acute Cholecystitis After EUS-guided Transmural Gallbladder Drainage: FUGITIVE Trial (FUGITIVE)

An interventional study of Cholecystoscopy and gallbladder cleaning in Acute Cholecystitis, sponsored by Hospital General Universitario de Alicante. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Hospital General Universitario de Alicante · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Cholecystitis, Acute with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Cholecystitis, Acute · Spain.

Started
2025
with 1 other
No phase
5 of 13
5 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Hospital General Universitario de Alicante

Among the 13 studies in Cholecystitis, Acute with a site in Spain, this one is one of 2 that started in 2025, is one of 5 with no phase, and was the 10th registered.

Cholecystitis, Acute

140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.

Browse Cholecystitis, Acute studies →

Open to participants now

7 of the 13 studies in Cholecystitis, Acute with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 21 Cholecystitis, Acute studies recruiting now, 17 (81%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cholecystitis, Acute with a site in Spain, or all of them as a file.
02

Study summary

Patients with gallbladder inflammation (acute cholecystitis) who cannot undergo surgery due to their fragility and surgical risk require a gallbladder drainage. It has been confirmed in previous studies that the gallbladder drainage from the digestive tract is a better alternative, because it has fewer complications than external (percutaneous) gallbladder drainage. However, there are no known studies that demonstrate whether it is better to maintain this drainage indefinitely, or to carry out periodic revisions of the drainage to progressively remove the stones lodged in the gallbladder and remove the drainage once this has been achieved. In this study we aim to compare the clinical evolution of patients who undergo this gallbladder drainage, dividing them into two groups:

  • One group of patients in whom we maintain a metallic prosthesis or stent, which communicates the gallbladder with the stomach, indefinitely in order to always guarantee a drainage of the bile towards the digestive tract, and thus avoid new episodes of cholecystitis.
  • Another group of patients who, one month after having undergone drainage, undergo a new procedure to remove the gallbladder lithiasis, until it is empty and without inflammation and we can remove the metal stent, leaving only a very thin plastic catheter to maintain the fistula and thus the bile continues to flow into the digestive tract. More than one procedure may be required to completely clear the gallbladder.

Knowledge of whether one strategy or the other presents fewer complications in the short, medium and long term is essential to be able to offer the best alternative to our patients.

The aim of the study is to compare the clinical outcome of these patients who have a definitive drain inserted with those who undergo several procedures to clear the gallbladder until the drain is removed. The rate of complications, the need for re-interventions and hospital admissions, new episodes of acute cholecystitis, quality of life and mortality of both groups over a period of one year are compared.

Read the detailed description

Laparoscopic cholecystectomy is the gold standard for treating acute cholecystitis (AC). However, not all patients are suitable candidates for surgery during an AC episode. After recovery, some may improve sufficiently to undergo preventive surgery for future biliary events, while others remain high-risk surgical candidates or fail to recover adequately, making surgery infeasible. For these high-risk patients, optimal management remains uncertain. Currently, percutaneous drainage is the standard treatment, with endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) emerging as a viable alternative in specialized centers. Recent data suggest that EUS-GBD may result in fewer complications compared to percutaneous drainage, with similar technical and clinical success rates.

Despite its promise, the optimal follow-up strategy for patients treated with EUS-GBD remains unclear, particularly regarding long-term complications associated with lumen-apposing metal stents (LAMS). Studies in pancreatic fluid collections suggest higher rates of complications, including bleeding and stent obstruction, leading to recommendations for early stent removal. However, for gallbladder drainage, the question arises whether LAMS should be maintained to prevent recurrence or replaced with less complication-prone stents like double pigtail stents.

The available evidence is contradictory. Some studies favor proactive endoscopic follow-up and gallstone removal to minimize recurrent cholecystitis, while others suggest that leaving LAMS indefinitely may reduce biliary events and hospital visits. To resolve these discrepancies, randomized prospective trials are needed to determine the optimal follow-up protocol for high-risk patients undergoing EUS-GBD for AC.

Our working hypothesis is that after EUS-GBD using a LAMS, there are no significant differences in the rate of biliopancreatic events between an active endoscopic approach (including gallbladder cleaning, stone extraction, and stent removal) and a conservative approach (without planned endoscopic interventions). Some studies even suggest that the proactive approach may lead to more complications The primary aim is to compare the rate of biliopancreatic events during one year of follow-up between patients treated with a proactive endoscopic strategy (group A) and those treated with a conservative strategy (group B) after EUS-GBD for acute cholecystitis (AC).

Secondary objectives focus on the evaluation of additional clinical outcomes, including complication rates at various time points, recurrence of biliary-related events, unplanned re-interventions, readmissions, mortality, disease-free survival, resolution of AC, and quality of life between the two groups.

This is a randomized, multicenter, open-label, nationwide, clinical trial. Patients will be randomized 1:1 to the two treatment groups stratified by center.

Centers eligible to participate as collaborating centers must have confirmed experience in EUS-guided procedures with EUS-GBD availability, having performed more than 10 EUS-GBD procedures prior to enrollment. Patient inclusion and exclusion criteria are specified in a separate section of the protocol.

For enrollment of patients, after diagnosis of AC, a patient evaluation by the surgical team or anesthesiologist declaring the patient unfit for surgery and the patient's willingness to undergo the EUS-GBD procedure is mandatory.

If the patient meets these requirements in addition to all previous inclusion criteria and none of the exclusion criteria, agrees to participate in the study, and signs the informed consent, the patient will be enrolled and randomized.

The randomization of patients to each of the treatment groups will be carried out centrally by the REDCap software; REDCap is a program that offers an online electronic data collection notebook. It will be stratified by center and by severity.

Patients will be randomized to two groups: Elective cholecystoscopy with stone extraction, eventual LAMS removal and double pigtail plastic stent (DPPS) placement or conservative management (indwelling LAMS). A total of 41 patients will be assigned to each group. In the group assigned to receive endoscopic interventions, upper gastrointestinal endoscopy will be programmed 4 weeks after de EUS-GBD and sequential procedures weekly thereafter until complete clearance of stones is achieved and the LAMS is removed and replaced with DPPS.

The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anaesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.

Gallbladder drainage will be performed with a LAMS, with a preference for stents ≥15 mm in diameter, and the preferred route will be duodenal (cholecystoduodenostomy); however, the final decision regarding stent size and route will be at the operator's discretion. After placement of the LAMS, a coaxial DPPS is placed. The DPPS complements the drainage and prevents complications.

After confirmation that the patient meets the inclusion criteria and none of the exclusion criteria, and after signing the informed consent form, the patient will undergo gallbladder drainage with a LAMS. The patient will then be randomized at their hospital to either group A (proactive treatment) or group B (conservative treatment). Randomization will not occur until after the drainage procedure has been completed.

Patient randomization in this clinical trial will be stratified by center to ensure an equal distribution of patients between the two intervention groups (proactive and conservative approaches) at each participating hospital. This stratification is essential to minimize potential center-specific differences that could influence outcomes.

Randomization sequences will be pre-generated using specialized software with blocks of four patients. Each block will randomly assign two patients to the proactive intervention group and two to the conservative group. This block design ensures that within each center, patients are sequentially and evenly assigned to both groups throughout the recruitment process, maintaining a constant balance. This approach is particularly critical because the trial may be stopped before the full expected sample size is reached.

The in-hospital management of patients with AC after EUS-GBD will be under the care of their attending physicians in the in-hospital ward of the respective collaborating center, who will follow the management recommended by the clinical guidelines. Their discharge will be decided by their regular physician. A clinical evaluation and laboratory tests will be performed 1 day and 7 days after the procedure (if the patient has not been discharged yet).

Periodic follow-up contacts are made: at 1 month, 6 months, 9 months, and 1 year. Contacts may be made by face-to-face or telematic visits after consultation with the patient, especially if the patient is institutionalized or has severe mobility problems. Additional laboratory tests are performed at the 1-month, 6-month and 1-year visits.

At these contacts, complications related to treatment and biliopancreatic events (BPE) that have occurred since the last visit are recorded. An interview will be conducted to record the presence of BPE that did not require admission (such as biliary colic or associated pain), recording the type and date of onset. The digital medical record will also be reviewed to record admissions and emergency department evaluations related or unrelated to BPE and to assess mortality.

03

Conditions studied

  • Acute Cholecystitis

Browse trials for

Keywords

  • EUS-guided gallbladder drainage
  • acute cholecystitis
  • interventional endoscopic ultrasonography
  • lumen apposing metal stents
  • percutaneous cholecystostomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient ≥ 18 years of age
  • Confirmed acute cholecystitis diagnosed according to Tokyo 2018 criteria.
  • Patient unfit for surgery: if meets one or more of the following criteria: age ≥ 80 years, American Society of Anesthesiology (ASA) ≥ III, Charlson Comorbidity Index > 5 and/or \< 50, or patient unwilling to undergo surgery.
  • Gallbladder drainage by LAMS stent.
  • signed

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate in the study
  • Gastrointestinal surgically modified anatomy preventing endoscopic access to the gallbladder.
  • Technical failure to perform endoscopic ultrasound guided-gallbladder drainage.
  • Moderate or severe ascites.
  • Severe coagulopathy >1.5 and/or fibrinogen \<120) or thrombocytopenia ( \<20,000).
  • Patient unable to tolerate sedation or general anesthesia
  • Haemodynamically unstable patient
  • \<6 months
  • Baseline ≥4
  • Patient with ongoing
  • Pregnancy
  • Acute pancreatitis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Active comparator
    Cholecystoscopy, gallbladder cleaning and removal of lumen-apposing metal stent

    Elective upper gastrointestinal endoscopy to perform cholecystoscopy, cleaning and removal of gallbladder (GB) stones and retrieval of the Lumen Apposing Metal Stent (LAMS) will be conducted 1 month after endoscopic ultrasound-guided GB drainage. For persistent GB stones, consecutive procedures will be performed weekly until complete cleaning and retrieval of the LAMS. A coaxial double pigtail plastic stent (7 or 10 Fr x 3 cm) will be placed indefinitely to maintain the fistula between the GB and the digestive tract.

    Procedure: Cholecystoscopy and gallbladder cleaning

  • No intervention
    Conservative treatment: Indwelling stent

    Patients in the conservative group will not be scheduled for endoscopic revision during the one-year follow-up. The LAMS will only be reviewed as part of routine practice for suspected LAMS related complications

Interventions

  • ProcedureCholecystoscopy and gallbladder cleaning

    Upper gastrointestinal endoscopy and cholecystoscopy are performed 4 weeks after GB drainage. A standard gastroscope is used to inspect the gallbladder cavity with retrieval or lithotripsy of residual stones until complete cleaning of the GB is achieved. Several procedures may be required to achieve complete stone clearance. Finally, the LAMS is retrieved and replaced with a double pigtail plastic stent.

06

What researchers measure

Primary outcomes

  1. Biliopancreatic events (BPE)

    The primary aim is to assess the difference in terms of recurrence of the combined variable of biliopancreatic events (biliary colic, cholangitis, choledocholithiasis, acute cholecystitis or acute pancreatitis) between the active treatment group and the conservative treatment group during follow-up period.

    Time frame: From enrollment until 12 months after

Secondary outcomes

  1. Recurrence of each of the variables that make up the combined variable BPE separately

    To assess and compare the recurrence of each individual variable that constitutes the combined variable BPE across groups (AP, cholangitis, choledocholithiasis, cholecystitis, biliary colic)

    Time frame: From enrollment until 12 months after

  2. Total complication rate

    The proportion of patients experiencing one or more complications during the study period

    Time frame: From enrollment until 12 months after

  3. Unplanned reintervention rate

    The percentage of patients requiring unplanned additional surgical, radiologic or endoscopic interventions

    Time frame: From enrollment until 12 months after

  4. Biliary cause admission rate

    The proportion of patients admitted to the hospital for biliary-related conditions

    Time frame: From enrollment until 12 months after

  5. Disease-Free survival

    The time from treatment initiation to disease recurrence or death from any cause

    Time frame: From enrollment until 12 months after

  6. Mortality rate

    The proportion of patients who die during the study period or within a defined follow-up time

    Time frame: From enrollment until 12 months after

  7. Recurrence rate of cholecystitis

    The proportion of patients experiencing a new episode of cholecystitis after initial resolution

    Time frame: From enrollment until 12 months after

  8. Clinical Success Rate for the Resolution of Cholecystitis

    The percentage of patients achieving complete resolution of cholecystitis symptoms with treatment

    Time frame: From enrollment until 12 months after

07

Study locations

1 of 2 sites recruiting
  • Hospital Universitario Dr Balmis Alicante
    Alicante, 03010, Spain
    Not yet recruiting
    • José Ramón Aparicio Tormo, MD · Contactdocenciamedica_hgua@gva.es · 0034 965 93 30 00
    • José Ramón Aparicio Tormo, MD · Principal investigator
    • Belén Martínez Moreno, MD · Sub investigator
    • Pedro López Muñoz, MD · Sub investigator
  • Hospital General Universitario Dr. Balmis
    Alicante, 03015, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 43 non-industry interventional studies with no phase under Cholecystitis, Acute, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 12 months is below that.

Counting every sponsor, half of 46 studies reached it within 20 months; a quarter within 9 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2025
First posted
May 13, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06967597
Lead sponsor
Hospital General Universitario de Alicante
Responsible party
Jose Ramon Aparicio Tormo (MD, Hospital General Universitario de Alicante) — Principal investigator
First posted
May 13, 2025
Start date
Jun 1, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 10, 2025

Study contacts

José Ramón Aparicio Tormo, MD
Contact
japariciot@gmail.com
(0034)965933468
Pedro López-Muñoz, MD
Contact
pedro.lopez8928@gmail.com
(0034)965933468

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion